LONDON, March 24, 2021 /PRNewswire/ -- The statement below is from Dr Moncef Slaoui in response to the announcement by GlaxoSmithKline plc today 24 March 2021.
It is with deep regret that I acknowledge today's statement from GlaxoSmithKline plc regarding my termination as Chair of the Galvani Board of Directors.
I have the utmost respect for my colleagues and feel terrible that my actions have put a former colleague in an uncomfortable situation.
I would like to apologise unreservedly to the employee concerned and I am deeply sorry for any distress caused.
I would also like to apologise to my wife and family for the pain this is causing.
I will work hard to redeem myself with all those that this situation has impacted.
I am taking a leave of absence from my current professional responsibilities effective immediately, to focus on my family.
The global autism spectrum disorder therapeutics market size is estimated to grow by USD 766.1 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 6.78% during the forecast period. Increasing prevalence of...
The global gastroesophageal reflux disease (GERD) market size is estimated to grow by USD 879.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 3.2% during the forecast period. Rising geriatric...
Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of...
Imperial Tobacco Canada Limited ("ITCAN") has officially submitted its feedback to Health Canada regarding the proposed Ministerial Order on nicotine replacement therapy products (NRTs). ITCAN strongly believes that NRTs, especially innovative...
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...
